Results 141 to 150 of about 7,051 (240)
Pre‐treatment DPYD and UGT1A1 genotyping is increasingly used to prevent fluoropyrimidine‐ and irinotecan‐related toxicity, but variant‐specific real‐world effects remain unclear. In an unselected cohort of cancer patients with actionable genotypes, genotype‐driven dosing improved safety while preserving treatment exposure in high‐risk DPYD c.1905+1G>A
Martina Gambron +12 more
wiley +1 more source
Optimising Genome-Wide Detection of Runs of Homozygosity: Impacts of Reference Genome Quality and Sequencing Parameters on Inbreeding Assessment. [PDF]
Shi M, Li H, Shafer ABA, Lan T.
europepmc +1 more source
Strategies and mechanisms of precision genome engineering: From gene editing to genome writing
In this review, we examined the progression of genome manipulation from stochastic nuclease‐mediated cutting toward precise editing and programmable genome writing. We discussed tools like multi‐kilobase RNA‐guided integrators and Artificial Intelligence (AI)‐designed effectors and showed how these advances enable researchers to treat genomes as ...
Kerui Huang +19 more
wiley +1 more source
Long runs of homozygosity are reliable genomic markers of inbreeding depression. [PDF]
Kyriazis CC, Robinson JA, Lohmueller KE.
europepmc +1 more source
EEG findings in SERAC1‐related MEGD(H)EL syndrome
Epileptic Disorders, EarlyView.
Apurva Patel, Dalila Lewis, Thomas Koch
wiley +1 more source
Metrnβ serves as a novel prognostic biomarker for sepsis and that targeted blockade of the Metrnβ‐c‐Kit axis represents a promising therapeutic strategy for sepsis. Abstract Sepsis is a heterogeneous syndrome critically driven by immunosuppression, yet lacking personalized prognostic markers and therapeutic targets. Here, we provide evidence to support
Xiao Li +15 more
wiley +1 more source
Genomic Characterization of Peruvian Creole Goats: Insights into Population Structure and Runs of Homozygosity. [PDF]
Corredor FA +11 more
europepmc +1 more source
A laboratory‐customized, open‐sequence TaqMan‐MGB probe assay was developed for detecting CYP2C19*2 and CYP2C19*17 polymorphisms using dried blood spot‐derived DNA. The assay demonstrated allele‐specific discrimination, candidate LODs of 1.17 × 102 copies/μL for CYP2C19*2 and 0.94 × 103 copies/μL for CYP2C19*17, and repeatability with CVs below 10%. In
Yaqun Liu +7 more
wiley +1 more source
Clinical utility of runs of homozygosity in the identification of genetic causes in individuals with rare diseases. [PDF]
Sivakumaran TA +7 more
europepmc +1 more source
Exploring Runs of Homozygosity and Heterozygosity in Sheep Breeds Maintained in Poland. [PDF]
Szmatola T +4 more
europepmc +1 more source

